Infinity Trident NMT SmartPod

Infinity Trident NMT SmartPod

Welcome to a Biomedical Battery specialist of the Draeger Battery

​The Infinity® Trident® NMT (neuromuscular transmission) SmartPod® provides an easy, accurate way to measure the level of muscle relaxation of patients under the influence of neuromuscular blocking agents. Trident parameters provide an objective indication of NMT by using an electrical stimulus of a peripheral nerve – enabling you to make an evidence-based judgment about the state of your patient’s neuromuscular blockade. The monitor with battery such as Kaden Yasen HYHB-498 Battery, Biolat BLT2012 Battery, Biolat BLT2003 Battery, Draeger MS14490 Battery, Draeger Medical Inc GAMMA Battery, Draeger Medical Inc Infinity DELTA Battery, Draeger Medical Inc SC 6002XL Battery, Draeger AS36059 Battery, Draeger Infinity Vista Battery, Draeger MS18340 Battery, Draeger Infinity DELTA XL Battery, Draeger Infinity GAMMA XL Battery can keep a long time runing.

◾Uses a standardized monitoring interface and alarm management feature
◾Quantifies the degree of muscle relaxation
◾Automatically integrates NMT parameters into the electronic patient record

​Trident assesses neuromuscular blockade by monitoring thumb acceleration (twitch response) during electrical stimulation of a peripheral nerve. The pod offers the following measuring capabilities:

◾Single Twitch: single stimulus with a response compared to a reference
◾Train-Of-Four (TOF): series of four impulses are given, results on TOF-ratio or TOF-count
◾Post-Tetanic Count: titanic stimulation, followed by single stimuli at one-second intervals is generated; the number of responses to the one second stimuli are counted

​NMT data is valuable before, during and after anesthesia in the operating room, and also when mechanical ventilation is used in the intensive care unit.

Monitoring NMT may help reduce the amount of neuromuscular blocking agents required during anesthesia, which could mean a shorter recovery period and a decrease in the post-operative incidence of neuromuscular weakness.